Pyxis Oncology, Inc. (PYXS)
2.03
+0.04
(+2.01%)
USD |
NASDAQ |
Oct 09, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Pyxis Oncology Enterprise Value : 112.14M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 112.14M |
| October 08, 2026 | 109.60M |
| October 07, 2026 | 110.87M |
| October 06, 2026 | 111.50M |
| October 05, 2026 | 125.46M |
| October 02, 2026 | 119.11M |
| October 01, 2026 | 122.29M |
| September 30, 2026 | 131.17M |
| September 29, 2026 | 167.33M |
| September 28, 2026 | 167.33M |
| September 25, 2026 | 164.79M |
| September 24, 2026 | 168.59M |
| September 23, 2026 | 187.62M |
| September 22, 2026 | 196.19M |
| September 21, 2026 | 185.72M |
| September 18, 2026 | 194.60M |
| September 17, 2026 | 199.68M |
| September 16, 2026 | 195.24M |
| September 15, 2026 | 194.60M |
| September 14, 2026 | 200.95M |
| September 11, 2026 | 186.99M |
| September 10, 2026 | 190.80M |
| September 09, 2026 | 197.77M |
| September 08, 2026 | 230.13M |
| September 04, 2026 | 230.13M |
| Date | Value |
|---|---|
| September 03, 2026 | 209.51M |
| September 02, 2026 | 221.24M |
| September 01, 2026 | 201.58M |
| August 31, 2026 | 188.89M |
| August 28, 2026 | 188.26M |
| August 27, 2026 | 193.97M |
| August 26, 2026 | 195.24M |
| August 25, 2026 | 177.47M |
| August 24, 2026 | 171.13M |
| August 21, 2026 | 178.74M |
| August 20, 2026 | 181.28M |
| August 19, 2026 | 197.14M |
| August 18, 2026 | 173.03M |
| August 17, 2026 | 174.94M |
| August 14, 2026 | 174.30M |
| August 13, 2026 | 174.30M |
| August 12, 2026 | 185.09M |
| August 11, 2026 | 162.88M |
| August 10, 2026 | 226.32M |
| August 07, 2026 | 219.98M |
| August 06, 2026 | 221.24M |
| August 05, 2026 | 181.92M |
| August 04, 2026 | 183.82M |
| August 03, 2026 | 176.21M |
| July 31, 2026 | 151.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
| Vericel Corp. | 1.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.35M |
| Total Expenses (Quarterly) | 25.35M |
| EPS Diluted (Quarterly) | -0.3961 |
| Earnings Yield | -69.13% |
| Normalized Earnings Yield | -69.13 |